重庆智翔金泰生物制药股份有限公司 对外担保管理制度 第一章 总则 第一条 为规范重庆智翔金泰生物制药股份有限公司（以下简称"公司"）对 外担保行为，控制公司经营风险，根据《中华人民共和国公司法》《中华人民共 和国民法典》《上海证券交易所科创板股票上市规则》等相关法律、行政法规和 规范性文件以及《重庆智翔金泰生物制药股份有限公司章程》（以下简称《公司 章程》）的规定，制定本制度。 第二条 本制度所述的对外担保系指公司及其控股或实际控制的子公司（以 下简称"控股子公司"）以第三人的身份为债务人对于债权人所负的债务提供担 保，当债务人不履行债务时，由公司按照约定履行债务或者承担责任的行为。 担保形式包括保证、抵押、质押或其他形式的担保。 对外担保包括公司为控股子公司提供的担保。 第四条 公司股东会和董事会是对外担保的决策机构，公司一切对外担保行 为，须按程序经公司股东会或董事会批准。 未经公司股东会或董事会的批准，公司不得对外提供担保。 公司控股子公司的对外担保，视同公司行为，其对外担保应执行本制度。 公司控股子公司的对外担保，应先按规定报由公司董事会或股东会决议后， 再由控股子公司股东会、董事会做具体决议。 1 ...

重庆智翔金泰生物制药股份有限公司 提名委员会工作细则 第一章 总则 第一条 为了规范公司董事、高级管理人员的产生程序，完善公司治理结构， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 等法律、法规和规范性文件以及《重庆智翔金泰生物制药股份有限公司章程》（以 下简称《公司章程》）的有关规定，制定本工作细则。 第二条 董事会下设提名委员会，主要负责对公司董事、总经理及其他高级 管理人员的人选、选择标准和程序等事项进行研究并提出建议。 第二章 人员组成 第三条 提名委员会由 3 名董事组成，其中独立董事应过半数。 第十条 提名委员会应就下列事项向董事会提出建议： 第四条 提名委员会委员由董事长提名，并由董事会选举产生。 选举委员的提案获得通过后，新任委员在董事会会议结束后立即就任。 第五条 提名委员会设主任委员（召集人）1 名，由独立董事委员担任，并 经提名委员会委员过半数推选产生，负责主持委员会工作。 第六条 提名委员会任期与同届董事会任期一致，委员任期届满，连选可以 连任。期间如有委员不再担任公司董事职务，自动失去委员资格，并由董事会根 据本工作细则第三条至第五条的规定补足委员人数。 ...

对外投资管理制度 重庆智翔金泰生物制药股份有限公司 第一章 总则 第一条 为加强重庆智翔金泰生物制药股份有限公司（以下简称"公司"） 对外投资活动的内部控制，规范对外投资行为，防范对外投资风险，保障对外投 资安全，提高对外投资效益，根据《中华人民共和国公司法》（以下简称《公司 法》）《上海证券交易所科创板股票上市规则》等法律、法规和规范性文件以及 《重庆智翔金泰生物制药股份有限公司章程》（以下简称《公司章程》）的规定， 结合公司实际情况，制定本制度。 第二条 本制度所称的对外投资，是指公司以现金、实物资产和无形资产等 作价出资，进行设立、并购企业（包括新设、参股、并购、重组、股权置换、股 份增持或减持等）、股权投资、委托管理以及国家法律法规允许的其他形式进行 的各项投资活动。但是，购买低风险银行理财产品的除外。 第三条 本制度中的公司资产是指本公司拥有及控制，能够以货币计量的， 并且能够产生效益的经济资源，包括由流动资产、长期投资、固定资产、无形资 产、递延资产以及其他资产等构成的各种财产、债权和其他权利。 第四条 公司所有对外投资行为必须符合国家有关法规及产业政策，符合公 司长远发展计划和发展战略，有利于拓 ...

重庆智翔金泰生物制药股份有限公司 关联交易管理制度 第一章 总则 第一条 为规范重庆智翔金泰生物制药股份有限公司（以下简称"公司"） 关联交易管理，明确管理职责和分工，维护公司股东和债权人的合法利益，特别 是中小投资者的合法利益，保证公司与关联方之间订立的关联交易合同符合公平、 公正、公开的原则，根据《中华人民共和国公司法》《中华人民共和国证券法》 等法律、法规和规范性文件以及《重庆智翔金泰生物制药股份有限公司章程》（以 下简称《公司章程》）的规定，制定本制度。 第二条 公司发生关联交易，应当保证关联交易的合法性、必要性、合理性 和公允性，保持公司的独立性，不得利用关联交易调节财务指标，损害公司利益。 第三条 公司股东会、董事会应当根据监管机构的相关规定、《公司章程》 及本制度的有关要求对关联交易实施管理。 第二章 关联人与关联交易的认定 第四条 公司的关联人，指具有下列情形之一的自然人、法人或其他组织： （一）直接或者间接控制公司的自然人、法人或其他组织； （二）直接或间接持有公司 5%以上股份的自然人； （三）公司董事或高级管理人员； （四）与上述第（一）、（二）、（三）项所述关联自然人关系密切的家庭 成 ...

第一章 总则 第一条 为充分发挥审计委员会对上市公司财务信息、内部控制、内外部审 计等工作的监督作用，健全上市公司内部监督机制，根据《中华人民共和国公司 法》（以下简称《公司法》）《中华人民共和国证券法》《上市公司治理准则》 《上市公司独立董事管理办法》等法律、法规和规范性文件以及《上市公司审计 委员会工作指引》《重庆智翔金泰生物制药股份有限公司章程》（以下简称《公 司章程》）的有关规定，制定本工作细则。 重庆智翔金泰生物制药股份有限公司 审计委员会工作细则 第二条 董事会下设审计委员会，依法履行《公司法》规定的监事会的职权， 主要负责审核公司财务信息及其披露、公司内、外部审计的沟通、监督和核查工 作。 第二章 人员组成和履职保障 第三条 审计委员会由 3 名董事组成，审计委员会成委员应当为不在公司担 任高级管理人员的董事，且其中独立董事应当过半数。审计委员会设主任委员（召 集人）1 名，由独立董事中会计专业人士担任，并经审计委员会成员过半数推选 产生，负责主持委员会工作。 第四条 审计委员会成员应当具备胜任工作职责的专业知识、工作经验和良 好的职业操守，保证足够的时间和精力履行委员会的工作职责，勤勉尽责，切 ...

Revenue and Profit - The company's revenue for the third quarter reached ¥162,163,555.96, representing a year-on-year increase of 1,199.88%[4] - The total profit for the period was -¥43,304,074.99, with a year-to-date total profit of -¥332,592,518.58[4] - The net profit attributable to shareholders was -¥43,304,074.99 for the quarter, and -¥332,592,518.58 year-to-date[4] - Total operating revenue for the first three quarters of 2025 reached ¥207,555,345.29, a significant increase from ¥12,487,909.78 in the same period of 2024, representing a growth of approximately 1,564%[20] - The net loss for the first three quarters of 2025 was ¥332,592,518.58, an improvement from a net loss of ¥546,344,400.70 in the same period of 2024, reflecting a reduction in losses of approximately 39%[22] - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.91, compared to -¥1.49 in 2024, showing an improvement in per-share loss[22] Research and Development - Research and development expenses totaled ¥130,019,225.62 for the quarter, a decrease of 15.78% compared to the previous year[5] - The ratio of R&D expenses to revenue was 80.18% for the quarter, a decrease of 1,157.36 basis points year-on-year[5] - Research and development expenses for the first three quarters of 2025 totaled ¥349,371,643.09, down from ¥437,938,634.20 in 2024, a decrease of about 20.2%[20] - The company has made progress in multiple research projects, including the approval of clinical trials for several new drugs in 2025[13] - The company has initiated Phase III clinical trials for several products, including GR1802 and GR2303, in 2025[13] - The company is actively pursuing new drug applications and market expansion strategies in the pharmaceutical sector[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,044,887,049.33, down 3.21% from the previous year[5] - The total assets as of the reporting date were ¥3,044,887,049.33, a decrease from ¥3,145,716,912.53 in the previous year[17] - Total liabilities increased to ¥1,257,059,870.69 from ¥1,019,674,124.99, representing an increase of approximately 23.3%[16] - The total equity attributable to shareholders decreased to ¥1,787,827,178.64 from ¥2,126,042,787.54, a decline of about 16%[17] Cash Flow - The net cash flow from operating activities was -¥261,194,455.74 year-to-date[5] - In the first three quarters of 2025, the company generated cash inflows from operating activities totaling CNY 285,516,431.51, compared to CNY 72,853,171.15 in the same period of 2024, representing a significant increase[23] - The net cash flow from operating activities for the first three quarters of 2025 was -CNY 261,194,455.74, an improvement from -CNY 422,511,071.20 in the previous year[24] - The company reported cash inflows from investment activities of CNY 1,770,409,731.34 in 2025, a substantial increase from CNY 27,716,207.53 in 2024[24] - Cash outflows for investment activities in 2025 amounted to CNY 2,305,911,650.66, compared to CNY 445,317,295.43 in the previous year, leading to a net cash flow from investment activities of -CNY 535,501,919.32[24] - The company raised CNY 237,245,626.11 from financing activities in 2025, up from CNY 126,755,335.17 in 2024[24] - The net cash flow from financing activities was CNY 175,721,044.63 in 2025, compared to CNY 97,396,813.24 in the previous year, indicating a positive trend[24] - The ending cash and cash equivalents balance as of September 2025 was CNY 1,414,518,108.42, down from CNY 2,149,425,057.07 at the end of the same period in 2024[24] - The company experienced a net decrease in cash and cash equivalents of -CNY 620,934,651.19 in 2025, compared to -CNY 742,715,345.86 in 2024, reflecting improved cash management[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,640[11] - The largest shareholder, Chongqing Zhirui Investment Co., Ltd., holds 200,000,000 shares, representing 54.54% of total shares[11] - The number of shares held by the top ten shareholders accounts for a significant portion of the company's equity, with the top shareholder alone holding over 54%[11] - The company has not reported any changes in the participation of major shareholders in margin financing or securities lending[12] Financial Performance - The weighted average return on net assets was -2.39% for the quarter, compared to -17.01% year-to-date[5] - The company reported a financial income of ¥30,799,073.38 in the first three quarters of 2025, down from ¥64,717,565.02 in 2024, a decrease of approximately 52.4%[20] - Total operating costs for the first three quarters of 2025 were ¥576,488,934.51, compared to ¥561,967,745.73 in 2024, indicating a slight increase of about 2.9%[20] - Sales expenses increased significantly to ¥170,484,290.90 in 2025 from ¥69,214,660.57 in 2024, marking an increase of approximately 146%[20] Accounting Standards - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the year[25]

证券代码：688443 证券简称：智翔金泰 公告编号：2025-047 重庆智翔金泰生物制药股份有限公司 关于取消监事会、修订《公司章程》及公司部分 治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开第二届董事会第五次会议，审议通过了《关于取消监事会、修订< 公司章程>并办理工商变更登记的议案》《关于修订公司部分治理制度的议案》。 公司于同日召开第二届监事会第四次会议审议通过了《关于取消监事会、修订< 公司章程>并办理工商变更登记的议案》。《关于取消监事会、修订<公司章程> 并办理工商变更登记的议案》和《关于修订公司部分治理制度的议案》的部分子 议案尚需提交公司股东大会审议，相关情况如下： 一、取消公司监事会、修订《公司章程》并办理工商变更登记的情况 根据《中华人民共和国公司法（2023 年修订）》（以下简称《公司法》）、 中国证券监督管理委员会《关于新<公司法>配套制度规则实施相关过渡期安排》 及《上市公司章程指引（20 ...

从资金流向上来看，当日生物制品板块主力资金净流出3.45亿元，游资资金净流入6848.58万元，散户资 金净流入2.77亿元。生物制品板块个股资金流向见下表： 证券之星消息，10月27日生物制品板块较上一交易日上涨0.33%，智翔金泰领涨。当日上证指数报收于 3996.94，上涨1.18%。深证成指报收于13489.4，上涨1.51%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688443 | 智别全泰 | 30.11 | 6.58% | 8.74万 | 2.61亿 | | 688331 | 荣昌生物 | 93.79 | 4.00% | 6.77万 | 6.37亿 | | 603087 | 甘李药业 | 71.52 | 3.91% | 12.97万 | 9.21亿 | | 301047 | 义翘神州 | 75.03 | 3.65% | 1.94万 | 1.44亿 | | 688105 | 诺唯赞 | 23.19 | 3.25% | 3.91万 | 9031.5 ...

Market Overview - The Shanghai Composite Index closed at 3986.15 points, above the annual line, with a gain of 0.91% [1] - The total trading volume of A-shares reached 1,933.9 billion yuan [1] Stocks Breaking Annual Line - A total of 63 A-shares have surpassed the annual line today, with notable stocks including Yongfu Co., Guotai Group, and Zhixiang Jintai, showing significant deviation rates of 15.69%, 7.57%, and 4.76% respectively [1] - Stocks with smaller deviation rates that just crossed the annual line include Changshan Beiming, Shangpin Home, and Lijiang Co. [1] Top Performers - Yongfu Co. (300712) saw a price increase of 18.71% with a turnover rate of 11.12%, latest price at 28.93 yuan, and a deviation rate of 15.69% [1] - Guotai Group (603977) increased by 10.00%, with a turnover rate of 6.21%, latest price at 13.53 yuan, and a deviation rate of 7.57% [1] - Zhixiang Jintai (688443) rose by 6.73%, with a turnover rate of 6.96%, latest price at 30.15 yuan, and a deviation rate of 4.76% [1] Additional Notable Stocks - Dahua Intelligent (002512) increased by 10.09% with a deviation rate of 4.08% [1] - Sierte (002538) rose by 5.90% with a deviation rate of 3.82% [1] - Tianyin Electromechanical (300342) increased by 4.23% with a deviation rate of 3.78% [1]

Core Insights - The Shanghai Stock Exchange STAR Market 100 Index has shown a strong increase of 1.42%, with notable gains from stocks such as Guandun Quantum (+11.49%) and Dongxin Co. (+6.59%) [3] - The STAR 100 Index ETF (588030) has risen by 1.34%, reaching a latest price of 1.36 yuan, and has accumulated a weekly increase of 4.92% as of October 24, 2025 [3] - The liquidity of the STAR 100 Index ETF is robust, with a turnover rate of 1.59% and a transaction volume of 97.23 million yuan [3] Industry Developments - Significant breakthroughs have been made in the photoresist sector, crucial for integrated circuit chip manufacturing, with a team from Peking University successfully analyzing the micro-3D structure of photoresist molecules [3] - The domestic computing power industry continues to show strong performance, with leading companies like Cambrian and Haiguang Information reporting substantial growth in Q3 and maintaining a high growth trend for the year [4] - The approval of IPOs for companies like Muxi Co. and the previous approval for Moole Technology indicate a surge in demand within the AI computing sector [4] Market Performance - The STAR 100 Index ETF has reached a scale of 5.988 billion yuan, ranking 2nd among comparable funds [4] - The STAR 100 Index consists of 100 medium-sized, liquid stocks selected from the STAR Market, reflecting the overall performance of different market capitalization companies [4] - As of September 30, 2025, the top ten weighted stocks in the STAR 100 Index account for 24.32% of the index, including companies like Huahong Semiconductor and BeiGene [4]